Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

Christopher P. Cannon(Brigham and Women's Hospital), Sean Curtis(Merck & Co., Inc., Rahway, NJ, USA (United States)), Garret A. FitzGerald(Translational Therapeutics (United States)), Henry Krum(Monash University), Amarjot Kaur(Merck & Co., Inc., Rahway, NJ, USA (United States)), James A. Bolognese(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alise Reicin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Claire Bombardier(University Health Network), Michael E. Weinblatt(Brigham and Women's Hospital), Désirée van der Heijde(Maastricht University Medical Centre), Erland Erdmann(University of Cologne), Loren Laine(University of Southern California)
The Lancet
November 1, 2006
Cited by 521

Abstract


Related Papers

No related papers found

Powered by citation graph analysis